| Literature DB >> 31745860 |
Carlo Cervellati1, Alessandro Trentini2, Valentina Rosta2, Angelina Passaro3, Cristina Bosi3, Juana Maria Sanz3, Stefania Bonazzi3, Salvatore Pacifico4, Davide Seripa5, Giuseppe Valacchi2,6,7, Remo Guerini4, Giovanni Zuliani3.
Abstract
Beta-secretase (BACE1) is a key enzyme in the formation of amyloid-β; its activity/concentration is increased in brain and cerebrospinal fluid of patients with late-onset Alzheimer's disease (LOAD). Since BACE1 was found also in blood, we evaluated its potential as peripheral biomarker. To this aim, serum BACE1 activity was assessed in 115 subjects with LOAD and 151 controls. We found that BACE1 changed across groups (p < 0.001) with a 25% increase in LOAD versus controls. High levels of BACE1 (IV quartile) were independently associated with the diagnosis of LOAD (OR 2.8; 1.4-5.7). Diagnostic accuracy was 76% for LOAD. Our data suggest that increased BACE1 activity in serum may represent a potential biomarker for LOAD. Additional studies are needed to confirm the usefulness of BACE1, alone or in combination with other markers, in discriminating patients and predicting LOAD onset and progression.Entities:
Keywords: BACE1; Blood-based biomarkers; Late-onset Alzheimer’s disease; Mild cognitive impairment; Mixed dementia
Mesh：
Substances：
Year: 2019 PMID： 31745860 PMCID： PMC7031490 DOI： 10.1007/s11357-019-00127-6
Source DB: PubMed Journal: Geroscience ISSN： 2509-2723 Impact factor: 7.713